Wechselwirkungen · Cresemba
CRESEMBA 40 mg hard capsules CRESEMBA 100 mg hard capsules · Abschnitt 4.5 · PDF-Seite 34–35
HOS-129000 · Präparat HOS-096645
34 Antigout agent Colchicine Not studied. No isavuconazole dose (P-gp substrate) Colchicine concentrations may adjustment necessary. increase. Colchicine has a narrow therapeutic index and should be (P-gp inhibition) monitored, dose reduction if required. Natural products Caffeine Caffeine: No isavuconazole dose (CYP1A2 substrate) AUCinf: ↑ 4% adjustment necessary. Cmax: ↓ 1% Caffeine: no dose adjustment required. Smoking cessation aids Bupropion Bupropion: No isavuconazole dose (CYP2B6 substrate) AUCinf: ↓ 42% adjustment necessary. Cmax: ↓ 31% Bupropion: dose increase if required. (CYP2B6 induction) NNRTI, non-nucleoside reverse-transcriptase inhibitor; P-gp, P-glycoprotein. a) % decrease of the mean trough level values b) Indinavir was only studied after a single dose of 400 mg isavuconazole. AUCinf = area under the plasma concentration-time profiles extrapolated to infinity; AUCtau = area under the plasma concentration-time profiles during the 24 h interval at steady state; Cmax = peak plasma concentration; Cmin,ss = trough levels at steady state.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) bupropion (HOS-086329) caffeine (HOS-085902) colchicine (HOS-086147)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-24T19:07:53Z · SHA-256 717f0eaf344e7731233baaa73335921f17bfdd86e9fa04c8f2a3921c343e8f3d · Passage 07d61b75d2739550c308621d53ee4d897b7b0e2661ef77cd89bf533f1bb54a59 · Zeichen 25179–27139 im Abschnitt